[go: up one dir, main page]

EP0506813A1 - 5-ht 3? antagonists for treatment of nausea, bradycardia of hypotension associated with myocardial instability - Google Patents

5-ht 3? antagonists for treatment of nausea, bradycardia of hypotension associated with myocardial instability

Info

Publication number
EP0506813A1
EP0506813A1 EP91901843A EP91901843A EP0506813A1 EP 0506813 A1 EP0506813 A1 EP 0506813A1 EP 91901843 A EP91901843 A EP 91901843A EP 91901843 A EP91901843 A EP 91901843A EP 0506813 A1 EP0506813 A1 EP 0506813A1
Authority
EP
European Patent Office
Prior art keywords
hydrogen
composition according
alkyl
treatment
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP91901843A
Other languages
German (de)
French (fr)
Inventor
Edward Stewart Smithkline Johnson
Thomas Conway Smithkline Hamilton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beecham Group PLC
Original Assignee
Beecham Group PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beecham Group PLC filed Critical Beecham Group PLC
Publication of EP0506813A1 publication Critical patent/EP0506813A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Definitions

  • the present invention relates to a method for the treatment and/or prophylaxis of nausea and bradycardia associated with myocardial instability .
  • EP-A-158532 and EP-A-237281 (A.H. Robins Company, Inc.), EP-A-67770 and EP-A-2666730 (Merrell Toraude et Compagnie), GB 2125398A, GB 2145416A and 2152049A (Sandoz Limited), EP-A-322016, 350129 and 350130 (Duphar international Research B.V.), EP-A-307172 and US 4921982 (Eli Lilly and Company), EP-A-323077, EP-A-306148 and GB 2208385A and EP-A-361629 (John Wyeth and Brother Limited), EP-A-234872 (Adria Laboratories Inc.), EP-A-294292 (Adir et Compagnie), EP-A-339950, US 4924010, 4920219, 4290227 and WO90/6309 (Rorer International (overseas), Inc.), EP-A-309423 and EP- A-
  • EP-A-358903 disclose classes of compounds containing a saturated azacyclic or azabicyclic moiety, such as tropanyl, granatyl or quinuclidinyl, and are 5-HT 3 receptor antagonists.
  • EP-A-242973 EP-A-276163, EP-A-291172, EP-A-307145,
  • EP-A-357414, EP-A-357415, EP-A-357416, EP-A-357417, EP-A-364274 and EP-A-385722 (Glaxo Group Limited), EP-A-315316 (Beecham Group p.l.c), EP-A-361317 (Fujisawa), EP-A-375045 and EP-A-377238 (Duphar), EP-A-376624 and EP-A-381422 (Yamanouchi Pharmaceutical Co. Ltd.), EP-A-392663 (Ono Pharmaceutical Co.
  • EP-A-373061 (Adir et Compagnie)
  • US 4914207 Pfizer
  • GB 2229182A Merck Sharp and Dohme Limited
  • EP-A-201165 (Beecham Group p.l.c.) discloses the use of 5-HTo receptor antagonists, in particular MDL 72222 (Example 1), ICS 205-930 (Example 2) and ondansetron (Example 5) as antiemetic agents.
  • EP-A-200444 (Example 6) discloses the 5-HT 3 receptor antagonist, granisetron, which is also disclosed as an antiemetic agent. Ondansetron and granisetron are under clinical evaluation as antiemetic agents in cytotoxic drug induced emesis.
  • Myocardial instability occurs as a result of myocardial infarction, myocardial reperfusion following thrombolysis, percutaneous transluminal coronary angioplasty (PTCA), coronary bypass grafts and coronary cardiac catheterisation. Nausea, bradycardia (slowing of the heart) and hypotension as a result of myocardial instability is well known (E. Braunwald, Heart Disease' publ. Saunders pp. 1197-8, 1236, 1253, 1264), and there is a need for a suitable treatment to overcome these problems.
  • PTCA percutaneous transluminal coronary angioplasty
  • 5-HT 3 receptor antagonists such as compounds of the above classes, are of potential use in the treatment or prophylaxis of nausea, bradycardia and/or hypotension associated with myocardial instability.
  • the present invention provides a method for the treatment and/or prophylaxis of nausea and bradycardia and/or hypotension associated with myocardial instability in mammals, such as humans, which method comprises administering to the mammal in need of such treatment and/or prophylaxis an effective and/or prophylactic amount of a 5-HT 3 receptor antagonist, such as a compound of formula (I), or a pharmaceutically acceptable salt thereof:
  • a 5-HT 3 receptor antagonist such as a compound of formula (I), or a pharmaceutically acceptable salt thereof:
  • X is a phenyl group or a monocyclic 5 or 6 membered heteroaryl group, either of which group is optionally fused to a saturated or unsaturated 5-7 membered carbocyclic or heterocyclic ring;
  • A is a linking moiety; and
  • R is a saturated azabicyclic moiety or an imidazolyl moiety.
  • X may be unsubstituted or substituted, usually by one or more substituents selected from halogen, C 1-6 alkoxy, C1-6 alkylthio, C 1-6 alkyl, hydroxy, amino, C 1-6 alkylamino, C 1-7 alkanoylamino, or two substituents on X (when fused), may be linked to form a saturated or unsaturated optionally substituted carbocyclic ring.
  • Heteroatoms for heteroaryl and heterocyclic groups are selected from oxygen, nitrogen and sulphur.
  • X may be joined to A by an aromatic carbon atom, or (when X is fused), by a carbocyclic ring carbon atom, or by a heterocyclic ring carbon or nitrogen atom.
  • A is attached at an aromatic carbon atom, it is preferably attached at the aromatic carbon adjacent a 'fused' carbon atom, which is attached to the heteroatom of a heterocyclic ring in formula (I).
  • Suitable examples of X are as described in the aforementioned patent publications relating to 5-HT 3 receptor antagonists containing a saturated azabicyclic moiety, the subject matter of which is incorporated herein by reference.
  • Suitable examples of A include CONH (amide), COO (ester), NHCONH (ureide), CONHCONH (extended ureide), or a group of structure (h):
  • dotted circle represents two double bonds in any position in the 5 membered ring;
  • two of G, H and I are selected from oxygen, sulphur, nitrogen and carbon and the other is oxygen, sulphur or nitrogen;
  • E is a bond or C 1-5 alkylene optionally substituted by phenyl or hydroxy.
  • A may also be a keto - (methylene or ethylene) linkage, such as -CO-(CH 2 ) 2 -, or another of the linkages as described in the abovementioned patent publications relating to further classes of compounds having 5-HT 3 receptor antagonist activity containing an unsaturated N-heterocycle, in particular those in the name of Glaxo Group Limited.
  • the suitable X values in formula (I) which are described in the referenced patent publications, are that part of the structure remaining when the saturated azabicyclic moiety and A (where A is one of the suitable examples listed above), are disregarded.
  • Preferred examples of X include a group of sub-formula (a), (b), (c), (d), (e), (f) or (g):
  • R a to R e and R g are selected from hydrogen, halogen or hydroxy;
  • R 1 is hydrogen and R 2 is hydrogen or C 1- 4 alkyl; or R 1 and R 2 together are a bond;
  • R w are independently selected from hydrogen or C 1-6 alkyl;
  • R 12 is hydrogen, C 1-6 alkoxy or amino optionally substituted by a C 1-6 alkyl group, or R 12 is alkanoylamino; and
  • R 13 is halo, C 1-6 alkyl, C 1-6 alkoxy or C 1-6 alkylthio;
  • R 1 4 is hydrogen or C 1-6 alkyl; and L is CH or N.
  • moieties in alkyl or alkyl containing groups in R 1 to R 14 include methyl, ethyl, n- and iso-propvl, n-, iso-, sec- and tert-butyl, preferably methyl.
  • R 2 and R 4 or R 8 and R 9 when joined include C 2 , C 3 , C 4 , C 5 or C 6 polymethylene, preferably C 2 , C 3 , C 4 or C 5 polymethylene.
  • R a to R e and R g are preferably selected from hydrogen, fluoro, chloro and hydroxy, most preferably hydrogen.
  • - R b may be 5-, 6- or 7-chloro or fluoro.
  • X is of sub-formula (a)
  • one of R 1 and R 3 is preferably hydrogen and one or both of R 2 and R 4 (most preferably both) are alkyl groups, such as methyl, or are joined to form C 2-7 polymethylene; or when one of R 2 and R 4 is hydrogen, the other is preferably ethyl or n- or iso- propyl.
  • R 5 is preferably hydrogen or a methyl or ethyl group.
  • R 7 is preferably methyl.
  • R 8 and R 9 are preferably both methyl groups.
  • R 12 is preferably amino and R 13 is preferably chloro or bromo, most preferably chloro.
  • R 10 is preferably methoxy when C 1- 6 alkoxy.
  • R 9 and R 11 are preferably chloro or methyl and R 10 is preferably hydrogen.
  • R 14 is preferably hydrogen or methyl.
  • X is preferably a group of sub-formula (e).
  • R Suitable examples of R are as described in the aforementioned patent publications relating to 5-HT 3 receptor antagonists containing a saturated azabicyclic moiety.
  • R then include the groups of sub-formula (i), (j) and (k):
  • Z is (CH 2 ) n wherein n is 2 or 3, or Z is CH 2 -O-CH 2 ; p and q are independently 1 to 3; and R 15 or R 16 is methyl or ethyl, preferably methyl.
  • R is most preferably endo-9-azabicyclo [3.2.1] non-3-yl, endo-8-azabicyclo [3.2.1] oct-3-yl, 9-aza-3-oxabicyclo- [3.2.1]non-7-yl or 3-quinuclidinyl.
  • R may also be an imidazolyl group, in particular, 5-methyl-4-imidazolyl.
  • Examples of the compounds of formula (I) include the examples described in the aforementioned Patent Publications/References disclosing compounds containing a saturated azabicyclic moiety. Particular examples include MDL 72222, ICS 205-930 (tropisetron) and PU 46470A, described in Example 5 of EP-A-247266, and granisetron.
  • Examples of compounds of formula (I) also include the examples described in the aforementioned Patent Publications/References disclosing compounds containing an imidazolyl moiety, in particular, ondansetron and Examples 1, 2, 3, 4 and 5 in EP-A-315316 (Beecham Group p.l.c.).
  • 5-HT 3 receptor antagonists are as described and claimed in the aforementioned patent publications, in particular, those in the name of Glaxo Group Limited.
  • references to a5-HT 3 receptor antagonist including compounds of formula (I) and the specific compounds mentioned hereinbefore and salts thereof, include solvates such as hydrates.
  • 5-HT 3 receptor antagonists may be identified by standard methods, such as tests involving antagonism of the von Bezold Jarisch reflex, as described by Fozard J.R. et. al., J. Cardiovasc. Pharmacol. 2, 229-245 (1980).
  • the compounds of formula (I), including the specific compounds mentioned hereinbefore and salts thereof may be prepared as described in the aforementioned Patent Publications/References.
  • the 5-HT 3 receptor antagonist is in substantially pure pharmaceutically acceptable form.
  • the administration of the 5-HT 3 receptor antagonist may be by way of oral, sublingual, transdermal or parenteral administration.
  • Parenteral administration will generally be preferred, and the 5-HT 3 receptor antagonist administered during or after cardiac treatment (thrombolysis, PTCA, coronary bypass grafts, coronary and cardiac catheterisation).
  • cardiac treatment thrombolysis, PTCA, coronary bypass grafts, coronary and cardiac catheterisation.
  • the preferred administration may be pretreatment by way of oral, sublingual or transdermal administration.
  • a unit dose will normally contain 0.1 to 50 mg for example 0.5 to 10 mg, of the 5-HT 3 receptor antagonist, such as a compound of formula (I) or a pharmaceutically acceptable salt thereof.
  • Unit doses will normally be administered once or more than once a day, for example 2, 3, or 4 times a day, more usually 1 to 3 times a day, such that the total daily dose is normally in the range, for a 70 kg adult of 0.1 to 50 mg, for example 0.1 to 5 mg, that is in the range of approximately 0.001 to 1 mg/kg/day, more usually 0.005 to 0.2 mg/kg/day.
  • the 5-HT 3 receptor antagonist is administered in the form of a unit-dose composition, such as a unit dose oral or parenteral composition.
  • compositions are prepared by admixture and are suitably adapted for oral or parenteral administration, and as such may be in the form of tablets, capsules, oral liquid preparations, powders, granules, lozenges, reconstitutable powders, injectable and infusable solutions or suspensions or suppositories.
  • Tablets and capsules for oral administration are usually presented in a unit dose, and contain conventional excipients such as binding agents, fillers, diluents, tabletting agents, lubricants, disintegrants, colourants, flavourings, and wetting agents.
  • the tablets may be coated according to well known methods in the art.
  • Suitable fillers for use include cellulose, mannitol, lactose and other similar agents.
  • Suitable disintegrants include starch, polyvinylpyrrolidone and starch derivatives such as sodium starch glycollate.
  • Suitable lubricants include, for example, magnesium stearate.
  • Suitable pharmaceutically acceptable wetting agents include sodium lauryl sulphate.
  • compositions may be prepared by conventional methods of blending, filling or tabletting. Repeated blending operations may be used to distribute the active agent throughout those compositions employing large quantities of fillers. Such operations are, of course, conventional in the art.
  • Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups, or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use.
  • Such liquid preparations may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenated edible fats, emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example, almond oil, fractionated coconut oil, oily esters such as esters of glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid, and if desired conventional flavouring or colouring agents.
  • suspending agents for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenated edible fats, emulsifying agents, for example lecithin, sorbitan monooleate
  • Oral formulations also include conventional sustained release formulations, such as tablets or granules having an enteric coating.
  • fluid unit dose forms are prepared containing the 5-HT 3 receptor antagonist and a sterile vehicle.
  • the compound depending on the vehicle and the concentration, can be either suspended or dissolved.
  • Parenteral solutions are normally prepared by dissolving the compound in a vehicle and filter sterilising before filling into a suitable vial or ampoule and sealing.
  • adjuvants such as a local anaesthetic, preservatives and buffering agents are also dissolved in the vehicle.
  • the composition can be frozen after filling into the vial and the water removed under vacuum.
  • Parenteral suspensions are prepared in substantially the same manner except that the compound is suspended in the vehicle instead of being dissolved and sterilised by exposure to ethylene oxide before suspending in the sterile vehicle.
  • a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound of the invention.
  • compositions will usually be accompanied by written or printed directions for use in the treatment concerned.
  • the present invention also provides the use of a5-HT 3 receptor antagonist, such as a compound of formula (I) or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment and/or prophylaxis of nausea, bradycardia and/or hypotension associated with myocardial instability.
  • a5-HT 3 receptor antagonist such as a compound of formula (I) or a pharmaceutically acceptable salt thereof
  • Such treatment and/or prophylaxis may be carried out as hereinbefore described.
  • the present invention further provides a pharmaceutical composition for use in the treatment and/or prophylaxis of nausea, bradycardia and/or hypotension associated with myocardial instability, which comprises a5-HT 3 receptor antagonist, such as a compound of formula (I) or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.
  • a5-HT 3 receptor antagonist such as a compound of formula (I) or a pharmaceutically acceptable salt thereof
  • a pharmaceutically acceptable carrier may be prepared in the manner as hereinbefore described.

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)

Abstract

Méthode de traitement et ou de prophylaxie de la nausée et de la bradycardie et/ou de l'hypotension associées à une instabilité myocardique chez les mammifères, par exemple chez l'homme. Cette méthode prévoit d'administrer aux mammifères nécessitant ce traitement et/ou cette prophylaxie une quantité efficace et/ou prophylactique d'un antagoniste du récepteur 5-HT3, par exemple un composé de formule (I): X-A-R, ou un sel de celui-ci pharmaceutiquement acceptable, où X est un groupe phényle ou un groupe hétéroaryle monocyclique à 5 ou 6 éléments. Dans un cas comme dans l'autre, chaque groupe est fusionné à un noyau carbocyclique ou hétérocyclique saturé on insaturé à 5-7 éléments; A est une partie de liaison; et R est une partie azabicyclique saturée ou une partie imidazolyle.Method of treatment and / or prophylaxis of nausea and bradycardia and / or hypotension associated with myocardial instability in mammals, for example in humans. This method provides for administering to mammals requiring this treatment and / or this prophylaxis an effective and / or prophylactic amount of a 5-HT3 receptor antagonist, for example a compound of formula (I): XAR, or a salt thereof. -this pharmaceutically acceptable, where X is a phenyl group or a 5- or 6-membered monocyclic heteroaryl group. In either case, each group is fused to a saturated carbocyclic or heterocyclic ring or 5-7 element unsaturated; A is a connecting part; and R is a saturated azabicyclic part or an imidazolyl part.

Description

5-HT3 ANTAGONISTS FOR TREA TMENT OF NAUSEA, BRADYCARDIA OF HYPOTENSION ASSOCIATED WITH MYOCARDIAL INSTABILTTY
The present invention relates to a method for the treatment and/or prophylaxis of nausea and bradycardia associated with myocardial instability .
EP-A-158265 , EP-A-200444 , EP-A-220011 , EP-A-215545 , EP-A-247266 , EP-A-230718 , EP-A-235878 , EP-A-254584 , EP-A-255297 , EP-A-261964 , EP-A-287196, EP-A-289170 , EP-A-315390 and EP-A-377967 (Beecham Group p. I.e.),
EP-A-158532 and EP-A-237281 (A.H. Robins Company, Inc.), EP-A-67770 and EP-A-2666730 (Merrell Toraude et Compagnie), GB 2125398A, GB 2145416A and 2152049A (Sandoz Limited), EP-A-322016, 350129 and 350130 (Duphar international Research B.V.), EP-A-307172 and US 4921982 (Eli Lilly and Company), EP-A-323077, EP-A-306148 and GB 2208385A and EP-A-361629 (John Wyeth and Brother Limited), EP-A-234872 (Adria Laboratories Inc.), EP-A-294292 (Adir et Compagnie), EP-A-339950, US 4924010, 4920219, 4290227 and WO90/6309 (Rorer International (overseas), Inc.), EP-A-309423 and EP- A-351385 (Instituto de Angeli S.p.A.), EP-A-313393 (Yoshitomi Pharmaceutical industries Limited) EP-A-378111 (Zambon), EP-A-376624 and EP-A-381422 (Yamanouchi), EP-A-328200 and EP-A-337547 (Merck, Sharp and Dohme Limited), EP-A-302699 (Fordonal), WO 90/14347 (Nippon Skinyaku Co. Limited) and EP-A-358903 (Dianippon Pharmaceutical Co. Ltd.) disclose classes of compounds containing a saturated azacyclic or azabicyclic moiety, such as tropanyl, granatyl or quinuclidinyl, and are 5-HT3 receptor antagonists.
GB 2153821A, EP-A-191562, EP-A-210840, EP-A-219193,
EP-A-242973, EP-A-276163, EP-A-291172, EP-A-307145,
EP-A-317088, EP-A-336759, EP-A-339959, EP-A-344015, EP-A-345956, EP-A-347229, EP-A-353983, EP-A-356098,
EP-A-357414, EP-A-357415, EP-A-357416, EP-A-357417, EP-A-364274 and EP-A-385722 (Glaxo Group Limited), EP-A-315316 (Beecham Group p.l.c), EP-A-361317 (Fujisawa), EP-A-375045 and EP-A-377238 (Duphar), EP-A-376624 and EP-A-381422 (Yamanouchi Pharmaceutical Co. Ltd.), EP-A-392663 (Ono Pharmaceutical Co. Limited), EP-A-373061 (Adir et Compagnie), US 4914207 (Pfizer) and GB 2229182A (Merck Sharp and Dohme Limited) describe further classes of compounds which also have 5-HT3 receptor antagonist activity, and containing an unsaturated N-heterocycle, such as an imidazolyl moiety.
EP-A-201165 (Beecham Group p.l.c.) discloses the use of 5-HTo receptor antagonists, in particular MDL 72222 (Example 1), ICS 205-930 (Example 2) and ondansetron (Example 5) as antiemetic agents. EP-A-200444 (Example 6) discloses the 5-HT3 receptor antagonist, granisetron, which is also disclosed as an antiemetic agent. Ondansetron and granisetron are under clinical evaluation as antiemetic agents in cytotoxic drug induced emesis.
Myocardial instability occurs as a result of myocardial infarction, myocardial reperfusion following thrombolysis, percutaneous transluminal coronary angioplasty (PTCA), coronary bypass grafts and coronary cardiac catheterisation. Nausea, bradycardia (slowing of the heart) and hypotension as a result of myocardial instability is well known (E. Braunwald, Heart Disease' publ. Saunders pp. 1197-8, 1236, 1253, 1264), and there is a need for a suitable treatment to overcome these problems.
It has now been discovered that 5-HT3 receptor antagonists, such as compounds of the above classes, are of potential use in the treatment or prophylaxis of nausea, bradycardia and/or hypotension associated with myocardial instability.
Accordingly, the present invention provides a method for the treatment and/or prophylaxis of nausea and bradycardia and/or hypotension associated with myocardial instability in mammals, such as humans, which method comprises administering to the mammal in need of such treatment and/or prophylaxis an effective and/or prophylactic amount of a 5-HT3 receptor antagonist, such as a compound of formula (I), or a pharmaceutically acceptable salt thereof:
X-A-R (I)
wherein
X is a phenyl group or a monocyclic 5 or 6 membered heteroaryl group, either of which group is optionally fused to a saturated or unsaturated 5-7 membered carbocyclic or heterocyclic ring; A is a linking moiety; and R is a saturated azabicyclic moiety or an imidazolyl moiety.
X may be unsubstituted or substituted, usually by one or more substituents selected from halogen, C1-6 alkoxy, C1-6 alkylthio, C1-6 alkyl, hydroxy, amino, C1-6 alkylamino, C1-7 alkanoylamino, or two substituents on X (when fused), may be linked to form a saturated or unsaturated optionally substituted carbocyclic ring.
Heteroatoms for heteroaryl and heterocyclic groups are selected from oxygen, nitrogen and sulphur.
X may be joined to A by an aromatic carbon atom, or (when X is fused), by a carbocyclic ring carbon atom, or by a heterocyclic ring carbon or nitrogen atom. When X is fused, and A is attached at an aromatic carbon atom, it is preferably attached at the aromatic carbon adjacent a 'fused' carbon atom, which is attached to the heteroatom of a heterocyclic ring in formula (I). X may also be further joined to A as defined hereinafter, when Y-R10 is N-B=N.
Suitable examples of X are as described in the aforementioned patent publications relating to 5-HT3 receptor antagonists containing a saturated azabicyclic moiety, the subject matter of which is incorporated herein by reference.
Suitable examples of A include CONH (amide), COO (ester), NHCONH (ureide), CONHCONH (extended ureide), or a group of structure (h):
(h)
wherein the dotted circle represents two double bonds in any position in the 5 membered ring; two of G, H and I are selected from oxygen, sulphur, nitrogen and carbon and the other is oxygen, sulphur or nitrogen; and E is a bond or C1-5 alkylene optionally substituted by phenyl or hydroxy.
A may also be a keto - (methylene or ethylene) linkage, such as -CO-(CH2)2-, or another of the linkages as described in the abovementioned patent publications relating to further classes of compounds having 5-HT3 receptor antagonist activity containing an unsaturated N-heterocycle, in particular those in the name of Glaxo Group Limited. For the avoidance of doubt, the suitable X values in formula (I) which are described in the referenced patent publications, are that part of the structure remaining when the saturated azabicyclic moiety and A (where A is one of the suitable examples listed above), are disregarded.
Preferred examples of X include a group of sub-formula (a), (b), (c), (d), (e), (f) or (g):
wherein
Ra to Re and Rg are selected from hydrogen, halogen or hydroxy; R1 is hydrogen and R2 is hydrogen or C1- 4 alkyl; or R1 and R2 together are a bond;
R3 to R7 are independently hydrogen or C1-6 alkyl; and R4 together with R2 may be C2-7 polymethylene when R1 is hydrogen; R8 and R9 are independently selected from hydrogen or C1-6 alkyl or R8 and R9 together are C2-6 polymethylene or C2-5 polymethylene interrupted by an -0- linkage; either R10 is hydrogen, C1-6 alkoxy, C3-8 cycloalkyloxy or C3-8 cycloalkyl C1-4 alkyloxy; or R10 is joined to Y so that Y-R10 i s N-B=N where B is N or CH; and R11 i s hydrogen, halo, C1-6 alkoxy or C1-6 alkyl; or R10 and R11 are joined to form -OCH (RURV) -E- wherein E is (CH2)n or NRwCO(CH2)m wherein n is 1 or 2 and m is 0 or 1 and Ru, Rv. and Rw are independently selected from hydrogen or C1-6 alkyl; R12 is hydrogen, C1-6 alkoxy or amino optionally substituted by a C1-6 alkyl group, or R12 is alkanoylamino; and R13 is halo, C1-6 alkyl, C1-6 alkoxy or C1-6 alkylthio; R1 4 is hydrogen or C1-6 alkyl; and L is CH or N.
Examples of moieties in alkyl or alkyl containing groups in R1 to R14 include methyl, ethyl, n- and iso-propvl, n-, iso-, sec- and tert-butyl, preferably methyl.
Suitable examples of R2 and R4 or R8 and R9 when joined include C2, C3, C4, C5 or C6 polymethylene, preferably C2, C3, C4 or C5 polymethylene.
Ra to Re and Rg are preferably selected from hydrogen, fluoro, chloro and hydroxy, most preferably hydrogen. - Rb may be 5-, 6- or 7-chloro or fluoro. When X is of sub-formula (a), one of R1 and R3 is preferably hydrogen and one or both of R2 and R4 (most preferably both) are alkyl groups, such as methyl, or are joined to form C2-7 polymethylene; or when one of R2 and R4 is hydrogen, the other is preferably ethyl or n- or iso- propyl.
When X is of sub-formula (b), R5 is preferably hydrogen or a methyl or ethyl group.
When X is of sub-formula (c), one of A and R6 is attached at the 1-position and the other is attached at the 3-position as depicted in sub-formula (c), and R6 is preferably methyl or ethyl.
When X is of sub-formula (d), R7 is preferably methyl.
When X is of sub-formula (e), R8 and R9 are preferably both methyl groups.
When X is of sub-formula (f), and R10 is C1- 6 alkoxy or is joined to Y, R12 is preferably amino and R13 is preferably chloro or bromo, most preferably chloro. R10 is preferably methoxy when C1- 6 alkoxy.
When X is of sub-formula (f), and R10 is hydrogen, R9 and R11 are preferably chloro or methyl and R10 is preferably hydrogen.
When X is of sub-formula (g), R14 is preferably hydrogen or methyl.
X is preferably a group of sub-formula (e).
Suitable examples of R are as described in the aforementioned patent publications relating to 5-HT3 receptor antagonists containing a saturated azabicyclic moiety.
Preferred examples of R then include the groups of sub-formula (i), (j) and (k):
wherein Z is (CH2)n wherein n is 2 or 3, or Z is CH2-O-CH2; p and q are independently 1 to 3; and R15 or R16 is methyl or ethyl, preferably methyl.
R is most preferably endo-9-azabicyclo [3.2.1] non-3-yl, endo-8-azabicyclo [3.2.1] oct-3-yl, 9-aza-3-oxabicyclo- [3.2.1]non-7-yl or 3-quinuclidinyl. R may also be an imidazolyl group, in particular, 5-methyl-4-imidazolyl.
Examples of the compounds of formula (I) include the examples described in the aforementioned Patent Publications/References disclosing compounds containing a saturated azabicyclic moiety. Particular examples include MDL 72222, ICS 205-930 (tropisetron) and PU 46470A, described in Example 5 of EP-A-247266, and granisetron.
Examples of compounds of formula (I) also include the examples described in the aforementioned Patent Publications/References disclosing compounds containing an imidazolyl moiety, in particular, ondansetron and Examples 1, 2, 3, 4 and 5 in EP-A-315316 (Beecham Group p.l.c.).
Examples of pharmaceutically acceptable salts are as described in the aforementioned European Patent references in the name of Beecham Group p.l.c, the subject matter of which is incorporated herein by reference.
Further 5-HT3 receptor antagonists are as described and claimed in the aforementioned patent publications, in particular, those in the name of Glaxo Group Limited.
References to a5-HT3 receptor antagonist, including compounds of formula (I) and the specific compounds mentioned hereinbefore and salts thereof, include solvates such as hydrates.
5-HT3 receptor antagonists may be identified by standard methods, such as tests involving antagonism of the von Bezold Jarisch reflex, as described by Fozard J.R. et. al., J. Cardiovasc. Pharmacol. 2, 229-245 (1980). The compounds of formula (I), including the specific compounds mentioned hereinbefore and salts thereof may be prepared as described in the aforementioned Patent Publications/References.
Preferably, the 5-HT3 receptor antagonist is in substantially pure pharmaceutically acceptable form.
The administration of the 5-HT3 receptor antagonist may be by way of oral, sublingual, transdermal or parenteral administration.
Parenteral administration will generally be preferred, and the 5-HT3 receptor antagonist administered during or after cardiac treatment (thrombolysis, PTCA, coronary bypass grafts, coronary and cardiac catheterisation). In the case of prophylaxis, however, the preferred administration may be pretreatment by way of oral, sublingual or transdermal administration.
An amount effective to treat the disorders hereinbefore described depends on the usual factors such as the nature and severity of the disorders being treated and the weight of the mammal. However, a unit dose will normally contain 0.1 to 50 mg for example 0.5 to 10 mg, of the 5-HT3 receptor antagonist, such as a compound of formula (I) or a pharmaceutically acceptable salt thereof. Unit doses will normally be administered once or more than once a day, for example 2, 3, or 4 times a day, more usually 1 to 3 times a day, such that the total daily dose is normally in the range, for a 70 kg adult of 0.1 to 50 mg, for example 0.1 to 5 mg, that is in the range of approximately 0.001 to 1 mg/kg/day, more usually 0.005 to 0.2 mg/kg/day.
For oral or parenteral administration, it is greatly preferred that the 5-HT3 receptor antagonist is administered in the form of a unit-dose composition, such as a unit dose oral or parenteral composition.
Such compositions are prepared by admixture and are suitably adapted for oral or parenteral administration, and as such may be in the form of tablets, capsules, oral liquid preparations, powders, granules, lozenges, reconstitutable powders, injectable and infusable solutions or suspensions or suppositories.
Tablets and capsules for oral administration are usually presented in a unit dose, and contain conventional excipients such as binding agents, fillers, diluents, tabletting agents, lubricants, disintegrants, colourants, flavourings, and wetting agents. The tablets may be coated according to well known methods in the art.
Suitable fillers for use include cellulose, mannitol, lactose and other similar agents. Suitable disintegrants include starch, polyvinylpyrrolidone and starch derivatives such as sodium starch glycollate. Suitable lubricants include, for example, magnesium stearate. Suitable pharmaceutically acceptable wetting agents include sodium lauryl sulphate.
These solid oral compositions may be prepared by conventional methods of blending, filling or tabletting. Repeated blending operations may be used to distribute the active agent throughout those compositions employing large quantities of fillers. Such operations are, of course, conventional in the art.
Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups, or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenated edible fats, emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example, almond oil, fractionated coconut oil, oily esters such as esters of glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid, and if desired conventional flavouring or colouring agents.
Oral formulations also include conventional sustained release formulations, such as tablets or granules having an enteric coating.
For parenteral administration, fluid unit dose forms are prepared containing the 5-HT3 receptor antagonist and a sterile vehicle. The compound, depending on the vehicle and the concentration, can be either suspended or dissolved. Parenteral solutions are normally prepared by dissolving the compound in a vehicle and filter sterilising before filling into a suitable vial or ampoule and sealing.
Advantageously, adjuvants such as a local anaesthetic, preservatives and buffering agents are also dissolved in the vehicle. To enhance the stability, the composition can be frozen after filling into the vial and the water removed under vacuum.
Parenteral suspensions are prepared in substantially the same manner except that the compound is suspended in the vehicle instead of being dissolved and sterilised by exposure to ethylene oxide before suspending in the sterile vehicle. Advantageously, a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound of the invention.
As is common practice, the compositions will usually be accompanied by written or printed directions for use in the treatment concerned.
The present invention also provides the use of a5-HT3 receptor antagonist, such as a compound of formula (I) or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment and/or prophylaxis of nausea, bradycardia and/or hypotension associated with myocardial instability. Such treatment and/or prophylaxis may be carried out as hereinbefore described.
The present invention further provides a pharmaceutical composition for use in the treatment and/or prophylaxis of nausea, bradycardia and/or hypotension associated with myocardial instability, which comprises a5-HT3 receptor antagonist, such as a compound of formula (I) or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier. Such compositions may be prepared in the manner as hereinbefore described.

Claims

Claims
1. A method for the treatment and/or prophylaxis of nausea and bradycardia and/or hypotension associated with myocardial instability in mammals, such as humans, which method comprises administering to the mammal in need of such treatment and/or prophylaxis an effective and/or prophylactic amount of a5-HT3 receptor antagonist.
2. Use of a5-HT3 receptor antagonist in the treatment and/or prophylaxis of nausea, bradycardia and/or hypotension associated with myocardial instability.
3. A pharmaceutical composition for use in the treatment and/or prophylaxis of nausea, bradycardia and/or hypotension associated with myocardial instability, which comprises a 5-HT3 receptor antagonist, and a pharmaceutically acceptable carrier.
4. A method, use or composition according to any one of claims 1, 2 or 3, wherein the 5-HT3 receptor antagonist is of formula (I), or a pharmaceutically acceptable salt thereof:
X-A-R (I)
wherein
X is a phenyl group or a monocyclic 5 or 6 membered heteroaryl group, either of which group is optionally fused to a saturated or unsaturated 5-7 membered carbocyclic or heterocyclic ring; A is a linking moiety; and
R is a saturated azabicyclic moiety or an imidazolyl moiety.
5. A method, use or composition according to claim 4 wherein X is of sub-formula (a), (b), (c), (d), (e), (f) or (g):
wherein
Ra to Re and Rg are selected from hydrogen, halogen or hydroxy;
R1 is hydrogen and R2 is hydrogen or C1-4 alkyl; or
R1 and R2 together are a bond;
R3 to R7 are independently hydrogen or C1- 6 alkyl; and
R4 together with R2 may be C2-7 polymethylene when R1 is hydrogen;
R8 and R9 are independently selected from hydrogen or C1- 6 alkyl or R8 and R9 together are C2-6 polymethylene or C2-5 polymethylene interrupted by an -0- linkage; either R10 is hydrogen, C1- 6 alkoxy, C3- 8 cycloalkyloxy or C3- 8 cycloalkyl C1- 4 alkyloxy; or R10 is joined to Y so that Y-R10 i s N-B=N where B is N or CH; and R11 is hydrogen, halo, C1- 6 alkoxy or C1- 6 alkyl; or R10 and R11 are joined to form -OCH (RURV) -E- wherein E is (CH2)n or NRwCO(CH2)m wherein n is 1 or 2 and m is 0 or 1 and Ru, Ry. and Rw are independently selected from hydrogen or C1- 6 alkyl; R12 is hydrogen, C1- 6 alkoxy or amino optionally substituted by a C1- 6 alkyl group, or R12 is alkanoylamino; and R13 is halo, C1- 6 alkyl, C1- 6 alkoxy or C1- 6 alkylthio; R14 is hydrogen or C1- 6 alkyl; and L is CH or N.
6. A method, use or composition according to claim 4 or 5 wherein A is CONH (amide), COO (ester), NHCONH (ureide), CONHCONH (extended ureide), or a group of structure (h) :
(h)
wherein the dotted circle represents two double bonds in any position in the 5 membered ring; two of G, H and I are selected from oxygen, sulphur, nitrogen and carbon and the other is oxygen, sulphur or nitrogen; and E is a bond or C1- 6 alkylene optionally substituted by phenyl or hyddoxy.
7. A method, use or composition according to claim 6 wherein R is of sub-formula (i), (j) or (k) :
wherein
Z is (CH2)n wherein n is 2 or 3, or Z is CH2-O-CH2; p and q are independently 1 to 3; and R15 or R16 is methyl or ethyl, preferably methyl.
8. A method, use or composition according to claim 7 wherein R is endo-9-azabicyclo [3.2.1]non-3-yl, endo-8-azabicyclo [3.2.1] oct-3-yl, 9-aza-3-oxabicyclo- [3.2.1]non-7-yl or 3-quinuclidinyl.
9. A method, use or composition according to claim 8 wherein the compound of formlula (I) is MDL 72222, ICS 205- 930, granisetron or PU 46470A.
10. A method, use or composition according to claim 4 or 5 wherein A is -CO- (CH2)2- and R is an imidazolyl moiety.
11. A method, use or composition according to claim 10 wherein R is 5-methyl-4-imidazolyl.
12. A method, use or composition according to claim 11 wherein the compound of formula (I) is ondansetron.
13. A method, use or composition according to claim 1, wherein the 5-HT3 receptor antagonist is as described herein with reference to the listed patent publications relating to 5-HT3 receptor antagonists.
EP91901843A 1989-12-21 1990-12-20 5-ht 3? antagonists for treatment of nausea, bradycardia of hypotension associated with myocardial instability Withdrawn EP0506813A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB8928837 1989-12-21
GB898928837A GB8928837D0 (en) 1989-12-21 1989-12-21 Pharmaceuticals

Publications (1)

Publication Number Publication Date
EP0506813A1 true EP0506813A1 (en) 1992-10-07

Family

ID=10668280

Family Applications (1)

Application Number Title Priority Date Filing Date
EP91901843A Withdrawn EP0506813A1 (en) 1989-12-21 1990-12-20 5-ht 3? antagonists for treatment of nausea, bradycardia of hypotension associated with myocardial instability

Country Status (9)

Country Link
EP (1) EP0506813A1 (en)
JP (1) JPH05502872A (en)
KR (1) KR920703037A (en)
AU (1) AU7051691A (en)
CA (1) CA2071994A1 (en)
GB (1) GB8928837D0 (en)
IE (1) IE904603A1 (en)
WO (1) WO1991009593A2 (en)
ZA (1) ZA9010219B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU676032B2 (en) * 1993-03-18 1997-02-27 F. Hoffmann-La Roche Ag Use of granisetron for the treatment of post-operative nausea and vomiting

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2699794B2 (en) * 1992-03-12 1998-01-19 三菱化学株式会社 Thieno [3,2-b] pyridine derivative
PE20021019A1 (en) 2001-04-19 2002-11-13 Upjohn Co SUBSTITUTED AZABYCLE GROUPS
AR036041A1 (en) 2001-06-12 2004-08-04 Upjohn Co HETEROCICLIC AROMATIC COMPOUNDS REPLACED WITH QUINUCLIDINE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
AR036040A1 (en) 2001-06-12 2004-08-04 Upjohn Co MULTICICLIC HETEROARYL COMPOUNDS REPLACED WITH QUINUCLIDINES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US6911543B2 (en) 2001-10-02 2005-06-28 Pfizer Inc. Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease
US6849620B2 (en) 2001-10-26 2005-02-01 Pfizer Inc N-(azabicyclo moieties)-substituted hetero-bicyclic aromatic compounds for the treatment of disease
JP2005510523A (en) 2001-11-09 2005-04-21 ファルマシア アンド アップジョン カンパニー リミティド ライアビリティー カンパニー Azabicyclic phenyl fused heterocyclic compounds and use of the compounds as α7NACHR ligands
DE10164139A1 (en) 2001-12-27 2003-07-10 Bayer Ag 2-heteroaryl carboxamides
MXPA04007936A (en) 2002-02-15 2004-11-26 Upjohn Co Azabicyclo-substituted benzoylamides and thioamides for treatment of cns-related disorders.
JP2005523288A (en) 2002-02-19 2005-08-04 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー Fused bicyclic-N-bridged-heteroaromatic carboxamides for disease treatment
AU2003217275A1 (en) 2002-02-19 2003-09-09 Pharmacia And Upjohn Company Azabicyclic compounds for the treatment of disease
CA2499128C (en) 2002-09-25 2012-07-31 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof
US7396833B2 (en) 2003-12-22 2008-07-08 Memory Pharmaceuticals Corporation Indoles, 1H-indazoles, 1,2-benzisoxazoles, and 1,2-benzisothiazoles, and preparation and uses thereof
CN103724343A (en) 2004-03-25 2014-04-16 记忆药物公司 Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof
CA2567977A1 (en) 2004-04-22 2006-01-05 Memory Pharmaceutical Corporation Indoles, 1h-indazoles, 1,2-benzisoxazoles, 1,2-benzoisothiazoles, and preparation and uses thereof
KR20070015607A (en) 2004-05-07 2007-02-05 메모리 파마슈티칼스 코포레이션 1H-indazole, benzothiazole, 1,2-benzoisoxazole, 1,2-benzoisothiazole, and chromone and preparation and use thereof
WO2006065686A2 (en) 2004-12-13 2006-06-22 Galileo Pharmaceuticals, Inc. Spiro derivatives as lipoxygenase inhibitors
WO2006069097A2 (en) 2004-12-22 2006-06-29 Memory Pharmaceuticals Corporation Nicotinic alpha-7 receptor ligands and preparation and uses thereof
US8106066B2 (en) 2005-09-23 2012-01-31 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof
CN103221411B (en) 2010-05-17 2016-05-11 富瑞姆制药公司 Crystal form of (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate
AU2013259871A1 (en) 2012-05-08 2014-11-20 Forum Pharmaceuticals Inc. Methods of maintaining, treating or improving cognitive function

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI74707C (en) * 1982-06-29 1988-03-10 Sandoz Ag FOERFARANDE FOER FRAMSTAELLNING AV TERAPEUTISKT ANVAENDBARA ALKYLENOEVERBRYGGADE PIPERIDYLESTRAR ELLER -AMIDER AV BICYKLISKA KARBOXYLSYROR.
DE3445377A1 (en) * 1983-12-23 1985-07-04 Sandoz-Patent-GmbH, 7850 Lörrach CARBOCYLIC AND HETEROCYCLIC CARBONIC ACID ESTERS AND AMIDES OF BRIDGED AND NON-BRIDGED CYCLIC NITROCYLINE AMINES OR ALCOHOLS
IL74165A (en) * 1984-01-25 1988-11-15 Glaxo Group Ltd 1,2,3,9-tetrahydro-3-(1h-imidazole-1-yl methyl)-4h-carbazol-4-one compounds,their preparation and pharmaceutical compositions containing them
EP0191562B1 (en) * 1985-01-23 1991-07-10 Glaxo Group Limited Tetrahydrocarbazolone derivatives
EP0200444B1 (en) * 1985-04-27 1992-11-11 Beecham Group Plc Azabicyclononyl-indazole-carboxamide having 5-ht antagonist activity
GB8518743D0 (en) * 1985-07-24 1985-08-29 Glaxo Group Ltd Heterocyclic compounds
GB8518745D0 (en) * 1985-07-24 1985-08-29 Glaxo Group Ltd Heterocyclic compounds
EP0247266B1 (en) * 1986-01-07 1993-03-10 Beecham Group Plc Indole derivatives having an azabicyclic side chain, process for their preparation, intermediates, and pharmaceutical compositions
GB8701494D0 (en) * 1987-01-23 1987-02-25 Glaxo Group Ltd Chemical compounds
ZA878096B (en) * 1986-11-03 1988-04-26 Merrell Dow Pharmaceuticals Inc. Esters of hexahydro-8-hydroxy-2,6-methano-2h-quinolizin-3(4h)-one and related compounds
GB8628475D0 (en) * 1986-11-28 1987-01-07 Glaxo Group Ltd Medicaments
FR2616149B1 (en) * 1987-06-04 1990-10-19 Adir NOVEL DERIVATIVE OF BENZO (B) THIOPHENE - 7 CARBOXYLIC ACID, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
ES2060655T3 (en) * 1987-09-03 1994-12-01 Glaxo Group Ltd DERIVATIVES OF LACTAMS.
GB8723157D0 (en) * 1987-10-02 1987-11-04 Beecham Group Plc Compounds
ATE108791T1 (en) * 1987-11-04 1994-08-15 Beecham Group Plc NEW 4-OXOBENZOTRIAZINE AND 4-OXOCHINAZOLINE.
DE3740984A1 (en) * 1987-12-03 1989-06-15 Sandoz Ag N-Oxides of heterocyclic carboxylic acid derivatives and their preparation and their use
NZ227229A (en) * 1987-12-10 1991-03-26 Duphar Int Res Indole derivatives and pharmaceutical compositions
DE3810552A1 (en) * 1988-03-29 1989-10-19 Sandoz Ag Esters and amides of indole-, benzo[b]thiophene or benzo[b]furancarboxylic acids or 4-amino-2-methoxybenzoic acids with N-heterocyclic or N-heterobicyclic alcohols or amines, processes for their preparation, pharmaceutical compositions containing them and applicator for administration thereof
US5116984A (en) * 1988-04-07 1992-05-26 Glaxo Group Limited Imidazole derivatives
EP0350129A1 (en) * 1988-07-07 1990-01-10 Duphar International Research B.V New annelated indoleketones with an imidazolylalkyl substituent
IT1226389B (en) * 1988-07-12 1991-01-15 Angeli Inst Spa NEW AMIDID AND GUANIDINE DERIVATIVES
FR2639944B1 (en) * 1988-12-06 1991-01-18 Adir NEW INDOLE DERIVATIVES, THEIR PREPARATION PROCESS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
CA2004911A1 (en) * 1988-12-22 1990-06-22 Mitsuaki Ohta 4,5,6,7-tetrahydrobenzimidazole derivatives
IT1228288B (en) * 1989-01-09 1991-06-07 Zambon Spa COMPOUNDS WITH ANTI-SEROTONIN ACTIVITY

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9109593A2 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU676032B2 (en) * 1993-03-18 1997-02-27 F. Hoffmann-La Roche Ag Use of granisetron for the treatment of post-operative nausea and vomiting

Also Published As

Publication number Publication date
KR920703037A (en) 1992-12-17
CA2071994A1 (en) 1991-06-22
IE904603A1 (en) 1991-07-03
AU7051691A (en) 1991-07-24
WO1991009593A2 (en) 1991-07-11
WO1991009593A3 (en) 1991-09-05
JPH05502872A (en) 1993-05-20
GB8928837D0 (en) 1990-02-28
ZA9010219B (en) 1991-11-27

Similar Documents

Publication Publication Date Title
EP0506813A1 (en) 5-ht 3? antagonists for treatment of nausea, bradycardia of hypotension associated with myocardial instability
EP0200444B1 (en) Azabicyclononyl-indazole-carboxamide having 5-ht antagonist activity
DE3689974T2 (en) Medicines to treat emesis.
KR880001291A (en) Therapeutic Uses of Serotonin Antagonists
EP0223385A2 (en) 8-Azabicyclo[3,2,1]octane and 9-azabicyclo[3,3,1]nonane derivatives
EP0340270B1 (en) 5-ht 3? receptor antagonists for treatment of cough and bronchoconstriction
US4786643A (en) Treatment of migraine, cluster headaches and trigeminal neuralgia
AU557463B2 (en) Dibenzodiazepinones
US4800225A (en) Pharmacologically active hydrated azabicyclo compound
EP0433043A1 (en) Medicaments
WO1994013284A1 (en) New use of 5-ht3 receptor antagonists
HK1004548B (en) Chemical compound
AU758936B2 (en) Method of treatment
US4956362A (en) Use of carpipramine for the treatment of anxiety and sleep disorders
EP0418327A1 (en) Antiemesis ergoline derivatives.
Alhaider Antihistamine, anticholinergic and cardiovascular effects of 2-substituted-4-phenylquinoline derivatives
GB2132189A (en) Tropyl and pseudotropyl benzoates and their use in migraine treatment
MXPA01000466A (en) Method of treatment

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19920525

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19940701